Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Healthy Participants 18 to 49 Years of Age

NCT07516418 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07516418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07516418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Healthy Participants 18 to 49 Years of Age
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Recruiting
Start date
April 15, 2026
Completion date
April 4, 2027
Enrollment
570 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

influenza a(h5n1), respiratory syncytial virus (rsv)